Drug Research
FDA Approves Zepatier (elbasvir and grazoprevir) for Chronic Hepatitis C Genotypes 1 and 4
The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV)...
Articles
Teva’s Dedication and Commitment Recognized by Patients
Fourth annual PatientView survey identifies Teva as a “Corporate Star” in the eyes of patients. Making medicines accessible is key to patient groups.
Teva's Dedication and...
Drug Research
AstraZeneca to collaborate with Cancer Research UK in screening for new cancer medicines at the AstraZeneca MRC UK Centre for Lead Discovery
AstraZeneca and Cancer Research UK today announced that they have signed a memorandum of understanding through which Cancer Research UK drug discovery investigators would be...
Drug Research
AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class ROR? inhibitors to treat auto-immune diseases
AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company, today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma...
Drug Research
AstraZeneca supports crowd sourcing challenge to find new combination therapies for cancer
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the...
Drug Research
Sanofi, Fraunhofer create new natural product center of excellence
French pharmaceutical firm Sanofi and Germany-based Fraunhofer-Gesellschaft have formed a natural product center of excellence to speed up the discovery and development of new therapies...
Drug Research
Galena Biopharma, Dr. Reddy’s partner for NeuVax in India
Galena Biopharma and Dr. Reddy's Laboratories have entered into a strategic development and commercialization partnership on NeuVax (nelipepimut-S) in India. NeuVax...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.